UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion

Frontiers in oncology, 2022-02, Vol.12, p.804330

2022

Volltextzugriff (PDF)

TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study

Current oncology (Toronto), 2022-10, Vol.29 (10), p.7411-7419

2022

Volltextzugriff (PDF)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

Current oncology (Toronto), 2022-09, Vol.29 (10), p.6749-6753

2022

Volltextzugriff (PDF)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

Frontiers in oncology, 2023-05, Vol.13, p.1159308

2023

Volltextzugriff (PDF)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

BMC cancer, 2023-07, Vol.23 (1), p.609-609, Article 609

2023

Volltextzugriff (PDF)

Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer

Frontiers in oncology, 2022-12, Vol.12, p.1035808-1035808

2022

Volltextzugriff (PDF)

Homologous recombination deficiency status predicts response to immunotherapy‐based treatment in non‐small cell lung cancer patients

Thoracic cancer, 2024-09, Vol.15 (25), p.1842-1853

2024

Volltextzugriff (PDF)

Research Progress of Targeted Therapy for HER2 Gene  in Advanced Non-small Cell Lung Cancer

Zhongguo fei ai za zhi, 2020-12, Vol.23 (12), p.1108-1112

2020

Volltextzugriff (PDF)

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer

Thoracic cancer, 2021-06, Vol.12 (11), p.1708-1715

2021

Volltextzugriff (PDF)

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

Molecular cancer, 2023-08, Vol.22 (1), p.124-124, Article 124

2023

Volltextzugriff (PDF)

Retrospective study of EGFR‐mutant lung adenocarcinoma with bone metastatic clinical features

Cancer reports, 2023-01, Vol.6 (1), p.e1628-n/a

2023

Volltextzugriff (PDF)

A deep learning‐based interpretable decision tool for predicting high risk of chemotherapy‐induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy

Cancer medicine (Malden, MA), 2023-09, Vol.12 (17), p.18306-18316

2023

Volltextzugriff (PDF)

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC

Clinical and translational medicine, 2023-02, Vol.13 (2), p.e1191-n/a

2023

Volltextzugriff (PDF)

Identification of a DNA damage repair gene‐related signature for lung squamous cell carcinoma prognosis

Thoracic cancer, 2022-04, Vol.13 (8), p.1143-1152

2022

Volltextzugriff (PDF)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920905424-1758835920905424

2020

Volltextzugriff (PDF)

Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation  in Non-small Cell Lung Cancer

Zhongguo Fei Ai Za Zhi, 2019-09, Vol.22 (9), p.583-589

2019

Volltextzugriff (PDF)

EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer

Thoracic cancer, 2020-02, Vol.11 (2), p.277-285

2020

Volltextzugriff (PDF)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR

Thoracic cancer, 2020-05, Vol.11 (5), p.1129-1138

2020

Volltextzugriff (PDF)

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study

Thoracic cancer, 2021-04, Vol.12 (8), p.1154-1161

2021

Volltextzugriff (PDF)

LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins

Cancer research (Chicago, Ill.), 2008-09, Vol.68 (18), p.7270-7277

2008

Volltextzugriff (PDF)

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer

Thoracic cancer, 2019-02, Vol.10 (2), p.226-233

2019

Volltextzugriff (PDF)

Sox7 Is an Independent Checkpoint for β-Catenin Function in Prostate and Colon Epithelial Cells

Molecular cancer research, 2008-09, Vol.6 (9), p.1421-1430

2008

Volltextzugriff (PDF)

2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition

Molecular cancer therapeutics, 2008-04, Vol.7 (4), p.809-817

2008

Volltextzugriff (PDF)

LKB1 mutation in large cell carcinoma of the lung

Lung cancer (Amsterdam, Netherlands), 2006-09, Vol.53 (3), p.285-294

2006

Volltextzugriff (PDF)

Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response

Translational oncology, 2022-10, Vol.24, p.101493-101493

2022

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(53)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(50)
Science & Technology
(50)
Humans
(29)
Mutation
(19)
Lung Cancer
(18)
Lung Neoplasms - Pathology
(17)
Respiratory System
(17)
Chemotherapy
(16)
Lung Neoplasms - Genetics
(15)
Original
(14)
Cancer Therapies
(13)
Carcinoma, Non-Small-Cell Lung - Pathology
(13)
Carcinoma, Non-Small-Cell Lung - Genetics
(12)
Lung Neoplasms - Drug Therapy
(12)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(11)
Metastasis
(9)
Cancer
(8)
Erbb Receptors - Genetics
(8)
Cell Line, Tumor
(7)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion

TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer

Homologous recombination deficiency status predicts response to immunotherapy‐based treatment in non‐small cell lung cancer patients

Research Progress of Targeted Therapy for HER2 Gene  in Advanced Non-small Cell Lung Cancer

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

Retrospective study of EGFR‐mutant lung adenocarcinoma with bone metastatic clinical features

A deep learning‐based interpretable decision tool for predicting high risk of chemotherapy‐induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC

Identification of a DNA damage repair gene‐related signature for lung squamous cell carcinoma prognosis

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation  in Non-small Cell Lung Cancer

EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study

LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer

Sox7 Is an Independent Checkpoint for β-Catenin Function in Prostate and Colon Epithelial Cells

2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition

LKB1 mutation in large cell carcinoma of the lung

Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response

Aktive Filter

Suchergebnisse filtern